Combined amiodarone and silymarin treatment, but not amiodarone alone, prevents sustained atrial flutter in dogs

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 8, 2003, Pages 861-867

  Vereckei, András ^a   Besch Jr , Henry R ^a   Zipes, Douglas P ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amiodarone toxicity; Antioxidants; Free radicals; Silymarin

Indexed keywords

AMIODARONE; ANTIOXIDANT; DEETHYLAMIODARONE; FREE RADICAL; SILYMARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TISSUE LEVEL; EXCITABLE GAP; FEMALE; HEART ATRIUM FLUTTER; HEART ATRIUM PACING; HEART CYCLE; HEART ELECTROPHYSIOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; REFRACTORY PERIOD;

AMIODARONE; ANIMALS; ATRIAL FLUTTER; CHRONIC DISEASE; DOGS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; MALE; SILYMARIN; TREATMENT OUTCOME;

EID: 0043011479     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2003.02446.x     Document Type: Article

References (45)

1. Vereckei A, Blázovics A, György I, Fehér E, Tóth M, Szénási G, Zsinka ÁJN, Földiák G, Fehér J: The role of free radicals in the pathogenesis of amiodarone toxicity. J Cardiovasc Electrophysiol 1993;4:161-177.
2. Vereckei A, Fehér E, Blázovics A, György I, Toncsev H, Fehér J: Free radical reactions in the pathomechanism of amiodarone liver toxicity. In Csomos G, Feher J, eds: Free Radicals and the Liver. Berlin: Springer Verlag, 1992, pp. 124-157.
3. Kennedy TP, Gordon GB, Paky A, McShone A, Adkinson NF Jr, Peters SP, Friday K, Jackman W, Sciuto AM, Gurtner GH: Amiodarone causes acute oxidant lung injury in ventilated and perfused rabbit lungs. J Cardiovasc Pharmacol 1988;12:23-36.
4. Hassan T, Kochevar IE, Abdulah D: Amiodarone phototoxicity to human erythrocytes and lymphocytes. Photochem Photobiol 1984;45:191-197.
5. Li ASW, Chignell CF: Spectroscopic studies of cutaneous photosensitizing agents-IX. A spin trapping study of the photolysis of amiodarone and desethylamiodarone. Photochem Photobiol 1987;45:191-197.
6. Paillous N, Verrier M: Photolysis of amiodarone an antiarrhythmic drug. Photochem Photobiol 1988;47:337-343.
7. Sautereau A-M, Toumaire C, Suares M, Tocanne J-F, Paillous N: Interactions of amiodarone with model membranes and amiodarone-photoinduced peroxidation of lipids. Biochem Pharmacol 1992;43:2559-2566.
8. Card JW, Leeder RG, Racz WJ, Brien JF, Bray TM, Massey TE: Effects of dietary vitamin E supplementation on pulmonary morphology and collagen deposition in amiodarone- and vehicle-treated hamsters. Toxicology 1999;133:75-84.
9. Ágoston M, Cabello R-G, Blázovics A, Fehér J, Vereckei A: The effect of amiodarone and/or antioxidant treatment on splenocyte blast transformation. Clin Chim Acta 2001;303:87-94.
10. Massey TE, Leeder RG, Rafeiro E, Brien JF: Mechanisms in the pathogenesis of amiodarone-induced pulmonary toxicity. Can J Physiol Pharmacol 1995;73:1675-1685.
11. Reasor MJ, Kacew S: An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Proc Soc Exp Biol Med 1996;212:297-304.
12. Hostetler KY, Reasor MJ, Waller ER, Yazaki PJ, Frazee BW: Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats. Biochim Biophys Acta 1986;875:400-405.
13. Hostetler KY, Giordano R, Jellison EJ: In vitro inhibition of lysosomal phospholipase A1 of rat lung by amiodarone and desethylamiodarone. Biochim Biophys Acta 1988;959:316-321.
14. Israel-Biet D, Venet A, Caubarrere I, Bonan G, Danel C, Chrétien J, Hance AJ: Bronchoalveolar lavage in amiodarone pneumonitis. Cellular abnormalities and their relevance to pathogenesis. Chest 1987;91:214-221.
15. Somani P, Bandyopadhyay S, Klaunig JE, Gross SA: Amiodarone- and desethylamiodarone-induced myelinoid inclusion bodies and toxicity in cultured rat hepatocytes. Hepatology 1990;11:81-92.
16. Feher J, Csomos G, Vereckei A: Free Radical Reactions in Medicine. Berlin: Springer Verlag, 1987, p. 117.
17. Gyönös I, Ágoston M, Kovács A, Szénási G, Vereckei A: Silymarin and vitamin E do not attenuate and vitamin E might even enhance the antiarrhythmic activity of amiodarone in a rat reperfusion arrhythmia model. Cardiovasc Drugs Ther 2001;15:233-240.
18. Rosenblueth A, Garcia Ramos J: Studies on flutter and fibrillation. II. The influence of artificial obstacles on experimental auricular flutter. Am Heart J 1947;33:677-684.
19. Frame LH, Page RL, Hoffmann BF: Atrial reentry around an anatomic barrier with a partially excitable gap. A canine model of atrial flutter. Circ Res 1986;58:495-511.
20. Heger JJ, Solow EB, Prystowsky EN, Zipes DP: Plasma and red blood cell concentrations of amiodarone during chronic therapy. Am J Cardiol 1984;53:912-917.
21. Flanagan RJ, Storey GCA, Holt DW: Rapid high performance liquid chromatographic method for measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy. J Chromatography 1980;187:391-398.
22. Storey GCA, Holt DW, Curry PVL: High-performance liquid chromatographic measurement of amiodarone and its desethyl metabolite: Methodology and preliminary observation. Ther Drug Monit 1982;4:384-388.
23. Ayers GM, Rho TH, Ben-David J, Besch HR Jr, Zipes DP: Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. J Cardiovasc Electrophysiol 1996;7:713-721.
24. Stambler BS, Wood MA, Ellenbogen KA: Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation. Electrophysiological determinants of enhanced conversion efficacy. Circulation 1997;96:4298-4306.
25. Nattel S, Courtemanche M, Wang Z: Functional and ionic mechanisms of antiarrhythmic drugs in atrial fibrillation. In Falk RH, Podrid PJ, eds: Atrial Fibrillation: Mechanisms and Management. Second Edition. Philadelphia: Lippincott-Raven Publishers, 1997, pp. 75-90.
26. Josephson ME: Atrial flutter and fibrillation. In Josephson ME, ed: Clinical Cardiac Electrophysiology. Techniques and Interpretations. Third Edition. Philadelphia: Lippincott, Williams & Wilkins 2002, pp. 272-321.
27. El-Sherif N: Experimental basis of drug action in atrial flutter and atrial fibrillation. In Saudi N, Schoels W, El-Sherif N, eds: Atrial Flutter and Fibrillation. From Basic to Clinical Applications. Armonk, NY: Futura Publishing Co., 1998, pp. 193-213.
28. Restivo M, Hegazy M, Caref EB, MJ, Assadi MA, El-Hamami M, Yin H, Piracha M, Brooks RR, El-Sherif N: Effects of azimilide dihydrochloride on circus movement atrial flutter in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 1996;7:612-624.
29. Anderson KP, Walker R, Dustman T, Lux RL, Ershler PR, Kates RE, Urie PM: Range-related electrophysiologic effects of long-term administration of amiodarone on canine ventricular myocardium in vivo. Circulation 1989;79:948-958.
30. Harris L, Chatelain P, Nokin P, Roncucci R: Pharmacology. In Harris L, Roncucci R, eds: Amiodarone. Pharmacology-Pharmacokinetics-Toxicology-Clinical Effects. Paris: MEDSI, 1986, pp. 3-44.
31. Kato R, Venkatesh N, Kamiya K, Yabek S, Kannan R, Singh BN: Electrophysiologic effects of desethylamiodarone, an active metabolite of amiodarone: Comparison with amiodarone during chronic administration in rabbits. Am Heart J 1988;115:351-359.
32. Berger Y, Harris L: Pharmacokinetics. In Harris L, Roncucci R, eds: Amiodarone. Pharmacology-Pharmacokinetics-Toxicology-Clinical Effects. Paris: MEDSI, 1986, pp. 45-98.
33. Baerman JM, Annesley T, Di Carlo LA Jr, Foley MK, Nicklas JM, BJ, Morady F: Interrelationship between serum levels of amiodarone, desethylamiodarone, reverse T3 and the QT interval during long term amiodarone treatment. Am Heart J 1986;111:644-648.
34. Holt DW, Tucker GT, Jackson PR, Storey GCA: Amiodarone pharmacokinetics. Am Heart J 1983;106:840-847.
35. Adams PC, Holt DW, Storey GCA, Morley AR, Callaghan J, Campbell RW: Amiodarone and its desethyl metabolite: Tissue distribution and morphologic changes during long term therapy. Circulation 1985;72:1064-1075.
36. Latini R, Connolly SJ, Kates RE: Myocardial disposition of amiodarone in the dog. J Pharmacol Exp Ther 1983;224:603-608.
37. Harris L, Munoz A: Clinical pharmacology. In Harris L, Roncucci R, eds: Amiodarone. Pharmacology-Pharmacokinetics-Toxicology-Clinical Effects. Paris: MEDSI, 1986, pp. 99-136.
38. Mitchell LB, Wyse DG, Gillis AM, Duff HJ: Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects. Circulation 1989;80:34-42.
39. Mostow NO, Rakita L, Vrobel TR, Noon D, Blumer J: Amiodarone: Intravenous loading for rapid suppression of ventricular arrhythmias. J Am Coll Cardiol 1984;4:97-104.
40. Rotmensch HH, Belhassen B, Swanson BN, Shoshani D, Spielman SR, Greenspon AJ, Greenspan AM, Vlasses PH, Horowitz LN: Steady state serum amiodarone concentrations: Relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med 1984;101:462-69.
41. Nattel S, Talajic M: Recent advances in understanding the pharmacology of amiodarone. Drugs 1988;36:121-131.
42. Nattel S, Talajic M, Fernini B, Roy D: Amiodarone: Pharmacology, clinical actions and relationships between them. J Cardiovasc Electrophysiol 1992;3:266-280.
43. Singh BN: Electropharmacologic properties of amiodarone. In Singh BN, ed: Control of Cardiac Arrhythmias by Lengthening Repolarization. Mount Kisco, NY: Futura Publishing Co., 1988, pp. 367-400.
44. Patterson E, Eller BT, Abrams GD, Vasiliades J, Lucchesi BR: Ventricular fibrillation in conscious canine preparation of sudden coronary death. Prevention by short and long amiodarone administration. Circulation 1983;68:857-864.
45. Katritsis D, Camm AJ: Amiodarone in long term prophylaxis. Drugs 1991;41(Suppl 2):54-66.